Cite
HARVARD Citation
Ratjen, F. et al. (2017). Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet. 5 (7), pp. 557-567. [Online].